Harvard Medical School - Massachusetts General Hospital (USA)
hôte : Nathalie Bonnefoy & Maeva Chauvin (IRCM)
Pr. David Pépin, Ph.D., is an Associate Professor of Surgery at Harvard Medical School and Massachusetts General Hospital. He trained as a molecular and developmental biologist, earning his doctorate at the University of Ottawa and completing postdoctoral training in reproductive biology and ovarian cancer research at MGH. His laboratory is focused on women’s health, from fertility to ovarian cancer. His team has pioneered research on the role of developmental hormone signals, such as anti?Müllerian hormone (AMH), in regulating the tumor microenvironment through stromal cells such as cancer?associated mesothelial cells (CAMCs). Pr. Pépin’s work combines advanced preclinical models and biological insights to uncover novel therapeutic targets for ovarian cancer and women’s health, bridging basic science with clinical applications.
Osaka University, Japon
host : JP. POUGET (IRCM)
Prof. Tadashi Watabe is an Associate Professor at the University of Osaka, Japan. He is a board-certified nuclear medicine physician with extensive expertise in theranostics and targeted alpha therapy. He serves as the principal investigator (PI) of investigator-initiated clinical trials of astatine (211At)-based targeted alpha therapy. The Alpha-T1 trial, which investigated [211At]NaAt in patients with radioiodine-refractory thyroid cancer, has been completed. He is currently leading the ongoing first-in-human Alpha-PS1 trial, which uses [211At]PSMA-5 targeting prostate-specific membrane antigen (PSMA) in patients with castration-resistant prostate cancer (NCT06441994). He is also the PI of several clinical studies involving [18F]FAPI-74, [18F]FBPA, and [11C]HCA2969. He has authored more than 170 peer-reviewed publications, with a primary research focus on the preclinical development of targeted alpha therapies using 211At and 225Ac, as well as theranostics related to FAPI, LAT1, and EphA2. He also serves as the Executive Congress Chair of the Theranostics World Congress 2027
ZEISS RMS Microscopy
hôte : A. DJIANE (IRCM)
Valérie de Crécy-Lagard, PhD
Distinguished Professor, AAAS & ASM fellow
Microbiology and Cell Science, University of Florida
"From Bacteria to Humans: Using Comparative Genomics to Reveal Hidden Gene Functions"
host: A . David (IRCM)
This talk highlights how comparative genomics, combined with biochemistry, structural biology, and machine learning, can uncover the functions of genes across all domains of life. It explains why functional annotation remains one of biology’s biggest challenges—due to paralogs, missing genes, inconsistent curation, and the limits of sequence?based prediction.
Through case studies, the presentation shows how bacterial model systems help solve long?standing mysteries in human biology. Examples include the discovery of the t6A tRNA?modification pathway, the functional and medical relevance of the PLPBP/YggS protein family, and the identification of the long?missing queuine/queuosine transporter in eukaryotes (SLC35F2). The talk emphasizes that accurate gene?function discovery requires integrative approaches and community?driven curation, as AI alone cannot yet resolve complex functional questions.
Centre d'Immunology Marseille-Luminy (CIML), Inserm
Host : P. Martineau (IRCM)
We longitudinally tracked the B-cell repertoires of 10 individuals after SARS-CoV-2 infection and repeated vaccinations. We reconstructed in vitro the naive sequences of a curated selection of 10,000 clonal lineages and measured their affinity for the spike protein binding domain of SARS-CoV-2. Our findings reveal that while the overall properties of the repertoire, including diversity, expansion, and V-gene usage, remained stable and similar to healthy individuals, the 'binder' lineages, whose naive sequence is capable of antigen binding, expanded more and had higher mutation rates. Their evolutionary patterns also differed markedly from non-binders. Among the binders, the high-affinity binder lineages showed the most activity and diversified more across the time points. We also demonstrate that lineages with identical naive sequences in different individuals evolve in similar ways. This comprehensive dataset of antibody-spike interactions in a real-world setting provides insights into detecting reacting clones within a repertoire and helps us understand how the functional diversity of the naive repertoire shapes the adaptive immune response to vaccination.
School of International Business, China Pharmaceutical University (CPU), China
This presentation offers a comparative overview of drug reimbursement policies for anticancer therapies across Asia and France, with a particular focus on oncology. Drawing on large-scale health insurance databases and electronic health record (EHR) systems, our team examines how reimbursement criteria and pharmaceutical benefits are shaped by real-world evidence, including safety profiles and treatment efficacy observed in patient cohorts. We aim to highlight key similarities and differences across health systems, and to discuss implications for policy and clinical practice
host: Prof E. DESHAYES (ICM)
Angiogenesis Research Group, School of Kinesiology and Health Science,
Muscle Health Research Centre, Faculty of Health, York University, Toronto, ON, Canada
host : L Linares (IRCM)
Institut de Génétique Humaine (IGH), UMR 9002
CNRS - Université de Montpellier
host : E. JULIEN(IRCM)
Situé dans le Parc Euromédecine, l'Institut de Recherche en Cancérologie de Montpellier (U1194) est localisé sur le Campus Val d'Aurelle (ICM, Institut régional du Cancer Montpellier / Val d'Aurelle).
Centre de Recherche U1194 soutenu par l'Inserm, l'Université de Montpellier et l'Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de
